← Back to Search

Ablation Catheter

Treatment Group for Ventricular Tachycardia

N/A
Recruiting
Research Sponsored by Abbott Medical Devices
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial aims to confirm the safety and effectiveness of the FlexAbility SE catheter for treating ventricular tachycardia. The device works by creating small scars in the heart to block abnormal electrical signals, helping to restore a normal heart rhythm. The study focuses on patients with this serious heart condition who may not respond well to other treatments. Catheter ablation has emerged as an important and effective treatment option for many recurrent ventricular arrhythmias.

Eligible Conditions
  • Ventricular Tachycardia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment GroupExperimental Treatment1 Intervention
Single Arm Group to receive ablation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FlexAbility SE Ablation Catheter
2018
N/A
~600

Find a Location

Who is running the clinical trial?

Abbott Medical DevicesLead Sponsor
647 Previous Clinical Trials
408,384 Total Patients Enrolled
Kristin Ruffner, PhDStudy DirectorClinical Program Director
9 Previous Clinical Trials
10,840 Total Patients Enrolled
~100 spots leftby Aug 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top